CD79a

CD79a

a type I transmembrane protein present on B cells that mediates signal transduction; expressed in mature B-cell neoplasms.
References in periodicals archive ?
Despite their postulated origin from postgerminal center B cells, primary effusion lymphoma cells are negative for B-cell markers such as CD19, CD20, and CD79a.
3) Tumors express various pan B-cell markers such as CD19, CD20 (Figure 2, A), CD22, and CD79a, but may lack one or more of these.
One of the most consistent and striking features of PBL is a marked decrease in the expression of B-lineage antigens, including CD20, CD79a, and PAX5.
At the US reference facility, The Ohio State University Comprehensive Cancer Center Pathology Core Research Laboratory (Columbus, Ohio), thin sections (4-[micro]m thick) of the tissue microarray were cut and stained with hematoxylin-eosin and monoclonal antibodies by immunohistochemistry against CD3, CD15, CD20, CD30, CD34, CD43, CD44, CD45, CD45RO, CD68, CD79a, CD138, Bcl-2, Bcl-6, immunoglobulin M (IgM), Ki-67, MUM-1, TdT (DAKO, Carpinteria, California), CD5, and CD10 (Novocastra, Bannockburn, Illinois); in situ hybridization Epstein-Barr virus, [kappa] and [lambda] light chains, and dual-color c-MYC gene break apart probe fluorescent in situ hybridization (FISH) FISHba c-MYC t(8;14) (Abbot/Vysis, Downer's Grove, Illinois).
By immunohistochemistry, the neoplastic cells are commonly positive for B-cell antigen markers, including CD20 (Figure 2, C) and CD79a.
As with low-grade nodal FL, most GI FLs express Bcl-2 and pan B-cell markers such as CD20 and CD79a.
For B-cell markers, HRS cells are positive for CD20 on a minority of the neoplastic cells with varied intensity in 30-40% of cases, CD79a is less often expressed.
Immunophenotypic classification of canine malignant lymphoma on formalin-fixed paraffin wax-embedded tissue by means of CD3 and CD79a cell markers.
Immunohistochemistry revealed positive staining of the tumor cells for CD43 and myeloperoxidase (negative for CD20, CD79a, CD30, CD99, CD3, CD138, AE1/3 and Cam 5.
The neoplastic lymphoid cells were positive for CD20 and CD79a but negative for CD3, CD4, CD5, CD8, CD10, CD30 and Bcl-2.
Markers that were negative (0%) included CD30 (n = 6), [kappa] light chain (n = 2), [lambda] light chain (n = 2), CD8 (n = 2), CD1a (n = 1), CD2 (n = 1), CD5 (n = 1), CD7 (n = 1), CD15 (n = 1), CD45RO (n = 1), CDw75 (n = 1), CD79a (n = 1), CD123 (n = 1), CD138 (n = 1), PAX5 (n = 1), TCL-1 (n = 1), and anaplastic lymphoma kinase (ALK; n = 1).